

SCIENTIFIC PROGRAMME

Thursday 6 April 2017

WS1	08.30–10.00	Pre-Congress Workshop: Hot HIV Topics in Latin America
WS1CH		Co-Chairs: <i>Ernesto Martínez-Buitrago, Infectious Diseases, Santiago de Cali, Colombia</i>
WS1CH		<i>Alejandro Afani, Latin American HIV Workshop Study Group, Santiago, Chile</i>
WS1CH		<i>Carlos Beltrán, Hospital Barros Luco Trudeau, and Universidad de Santiago, Santiago, Chile</i>
WS11	08.30–08.50	HIV in Latin America ‘a young epidemic’ <i>Pedro Zitko, Latin American HIV Workshop Study Group, Santiago, Chile</i>
WS12	08.50–09.10	Ladies first ‘always a problem’ <i>Isabel Cassetti, Helios Salud HIV Care Center, Buenos Aires, Buenos Aires, Argentina</i>
WS13	09.10–09.30	Too late to care ‘the same old story’ <i>Ana Paulina Celi, Armed Forces Hospital, Quito, Ecuador, and Pan American Association of Infectious Diseases</i>
WS14	09.30–10.00	Facing-up to the epidemic in Latin America: from evidence to action. Round table discussion
WS1CH		Led by: <i>Ernesto Martínez-Buitrago</i> <i>Alejandro Afani</i> <i>Carlos Beltrán</i>
WS1PL		Panellists: <i>Pedro Zitko</i> <i>Isabel Cassetti</i> <i>Ana Paulina Celi</i>
O11	10.00–10.15	Official Opening
O11CH		Co-Chairs: <i>Juan Sierra-Madero, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico</i>
O11CH		<i>Mauro Schechter, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil</i>
O111	10.15–10.45	The promise of curing HCV as a way of improving HIV treatment: a novel strategy <i>Carl Dieffenbach, National Institute of Allergy and Infectious Diseases, Bethesda, USA</i>
O112	10.45–11.15	Is it possible to cure HIV infection? A clinician’s perspective <i>Steven G Deeks, University of California, San Francisco, USA</i>
	11.15–11.30	Coffee
O12	11.30–13.00	Are Guidelines Guiding Latin American Care Providers?
O12CH		Co-Chairs: <i>Anton Pozniak, Chelsea and Westminster Hospital, London, UK</i>
O12CH		<i>Isabel Cassetti</i>
O12CH	11.30–11.50	Overview of international guidelines <i>Anton Pozniak</i>
O121	11.50–12.00	HIV/AIDS treatment guidelines: Mexico <i>Juan Luis Mosqueda Gómez, CAPASITS, Secretaria de Salud, León, Mexico</i>

SCIENTIFIC PROGRAMME (continued)

O122	12.00–12.10	HIV/AIDS guidelines on cART: the Brazilian perspective <i>Adele Schwartz Benzaken, Ministry of Health, Brasília, Brazil</i>
O123	12.10–12.20	ARV guidelines in Argentina <i>Carlos Zala, Director of the HIV/AIDS Program, Argentina Ministry of Health, and University of Buenos Aires, School of Medicine and Hospital Central de San Isidro, Buenos Aires, Argentina</i>
	12.20–13.00	Discussion
	13.00–14.00	Scientific Posters and lunch
O13	14.00–15.00	Two Challenges: HCV and Ageing
O13CH		Co-Chairs: <i>Marcelo Losso, Hospital General de Agudos JM Ramos Mejía, Buenos Aires, Argentina</i>
O13CH		<i>Mark Nelson, Chelsea and Westminster Hospital, London, UK</i>
O131	14.00–14.30	Treatment of hepatitis C: where are we now? <i>Mario Pessoa, University of São Paulo, São Paulo, Brazil</i>
O132*	14.30–14.45	Retreatment of patients failing AAD therapy in Spain in a real-life setting: updated results from the HEPCREsp GEHEP004 Cohort <i>Federico Garcia, Hospital Universitario San Cecilio, Granada, Spain</i>
O133*	14.45–15.00	Increased age-adjusted mortality and incidence of non-AIDS-defining events among people living with HIV enrolled after 50 years and aging in care in Latin America. A CCASAnet Cohort study <i>Pablo F Belaunzarán-Zamudio, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico</i>
O14	15.00–16.30	The 90s in the Americas
O14CH		Co-Chairs: <i>Juan Sierra-Madero</i>
O14CH		<i>Adele Schwartz Benzaken</i>
O141	15.00–15.15	Testing <i>Marcelo Losso</i>
O142	15.15–15.30	Treatment <i>Pedro Cahn, Fundación Huésped, Buenos Aires, Argentina</i>
O143	15.30–15.45	Retention in care/adherence <i>Carlos Beltrán</i>
O144	15.45–16.00	Prioritisation of treatment: is it necessary? <i>Mauro Schechter</i>
	16.00–16.30	Panel discussion
	16.30–17.00	Coffee

*Abstract accepted for oral presentation.

SCIENTIFIC PROGRAMME (continued)

SS1	17.00–18.30	Dolutegravir at the Core of Therapy ViiV Healthcare Satellite Symposium
SS1CH		Chair: <i>Isidoro Prudente Martínez, ViiV Healthcare, Santiago, Chile</i>
SS1CH	17.00–17.10	Introduction <i>Isidoro Prudente Martínez</i>
SS11	17.10–17.30	New guidelines in Brazil <i>Roberto Zajdenverg, GlaxoSmithKline, Rio de Janeiro, Brazil</i>
SS12	17.30–18.00	Dolutegravir in real life <i>Jan Van Lunzen, ViiV Healthcare, London, UK</i>
SS13	18.00–18.20	Case-based panel discussion <i>Pedro Cahn</i> <i>Jan Van Lunzen</i> <i>Roberto Zajdenverg</i>
SS14	18.20–18.30	Closure <i>Rodrigo Zilli Haanwinckel, GlaxoSmithKline, Rio de Janeiro, Brazil</i>
	18.30–19.30	Poster Reception

Friday 7 April 2017

SS2	09.00–10.30	Optimizing HIV Treatment in Latin America Gilead Sciences Satellite Symposium
SS2CH		Chair: <i>Carlos Beltrán</i>
SS21	09.00–09.25	HIV/AIDS treatment in Latin America: where are we now? <i>Carlos Beltrán</i>
SS22	09.25–09.50	HIV treatment strategies: the importance of integrase inhibitors <i>Anton Pozniak</i>
SS23	09.50–10.15	Diagnosis and treatment of neurologic opportunistic infections: what is important? <i>José Vidal Bermudez, University of São Paulo, São Paulo, Brazil</i>
	10.15–10.30	Discussion
	10.30–10.45	Coffee
O21	10.45–11.45	Adolescents Born with HIV: Life Must Go On In Collaboration with the International AIDS Society (IAS)
O21CH		Co-Chairs: <i>Monica Thormann, Salvador B Gautier Hospital, Santo Domingo, Dominican Republic</i>
O21CH		<i>Jean W Pape, Integrated Care Center and Research Institution, Les Centres GHESKIO, Port-au-Prince, Haiti</i>
O211	10.45–11.00	The second decade: cashing in on evolving capacities for better outcomes <i>Linda-Gail Bekker, The Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa, and President, International AIDS Society (IAS)</i>

SCIENTIFIC PROGRAMME (continued)

O212	11.00–11.15	Adolescents perspective <i>Daisy Machado, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil</i>
O213	11.15–11.30	MTCT: a paediatric perspective <i>Jorge Andrade Pinto, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil</i>
	11.30–11.45	Panel discussion
O22	11.45–12.45	Barriers to Treatment Success in Hepatitis C. Round table Discussion
O22CH		Co-Chairs: <i>Carl Dieffenbach</i>
O22CH		<i>Mario Pessoa</i>
O221	11.45–11.55	Access to drugs/treating patients <i>Pedro Cahn</i>
O222	11.55–12.05	Re-infection <i>Mark Nelson</i>
O223	12.05–12.15	When will I not treat anymore? <i>Esteban Gonzalez Ballerga, Hospital "José de San Martín", University of Buenos Aires, Buenos Aires, Argentina</i>
	12.15–12.45	Discussion
	12.45–13.45	Scientific Posters and lunch
CS1	13.45–15.00	Challenging Cases in Hepatitis Interactive Case Study Session
CS1CH		Co-Chairs: <i>Anton Pozniak</i>
CS1CH		<i>Ricardo Sobhie Diaz, Federal University of São Paulo, São Paulo, Brazil</i>
CS11	13.45–14.10	Case 1: hepatitis C co-infected case <i>Mario Pessoa</i>
CS12	14.10–14.35	Case 2: hepatitis B co-infected case <i>Mark Nelson</i>
CS13	14.35–15.00	Case 3: triple co-infected case <i>Jorge L. Santana, University of Puerto Rico School of Medicine, San Juan, Puerto Rico</i>
	15.00–15.15	Coffee
O23	15.15–16.45	PrEP in the Region
O23CH		Co-Chairs: <i>Roy M Gulick, Cornell Clinical Trials Unit, Weill Medical College, Cornell University, New York, USA</i>
O23CH		<i>Esper Georges Kallas, University of São Paulo, São Paulo, Brazil</i>
O231	15.15–15.40	Overview: where we are, what are the issues, what's coming? <i>Esper Georges Kallas</i>
O232	15.40–15.50	Rolling-out PrEP <i>Beatriz Grinsztejn, Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil</i>

SCIENTIFIC PROGRAMME (continued)

O233	15.50–16.00	Unseen benefits of PrEP programmes <i>Florentino Badial-Hernandez, Clínica Especializada Condesa Iztapalapa, Mexico City, Mexico</i>
O234	16.00–16.10	The importance of PrEP from a community perspective <i>Owen Ryan, International AIDS Society (IAS), Geneva, Switzerland</i>
	16.10–16.45	Discussion
	16.45–17.00	Coffee
SS3	17.00–18.30	Know Your Patients – Act Now! Merck Sharp & Dohme Satellite Symposium
SS3CH		Chair: <i>Mauro Schechter</i>
SS3CH	17.00–17.05	Opening remarks <i>Mauro Schechter</i>
SS31	17.05–17.20	Starting treatment for <u>YOUR</u> patient <i>Mauro Schechter</i>
SS32	17.20–17.50	Know your patient type: full assessment of the patient <i>José Luis Blanco, Hospital Clinic Universitari Barcelona, Barcelona, Spain</i>
SS33	17.50–18.20	Treatment durability and long-term success factors <i>Graeme Moyle, Chelsea and Westminster Hospital, London, UK</i>
	18.20–18.30	Q&A

Saturday 8 April 2017

SS4	09.00–10.00	HCV Treatment: from Clinical Trials to Real-world Experience Gilead Sciences Satellite Symposium
SS4CH		Chair: <i>Maria Cássia Mendes Correa, University of São Paulo, São Paulo, Brazil</i>
SS4CH	09.00–09.10	Introduction <i>Maria Cássia Mendes Correa</i>
SS41	09.10–09.30	Current and future challenges in hepatitis C <i>Samuel Navarro Álvarez, General Hospital Tijuana, Baja California, Mexico</i>
SS42	09.30–09.50	HCV treatment and challenging populations <i>Maria Cássia Mendes Correa</i>
	09.50–10.00	Discussion
	10.00–10.15	Coffee

SCIENTIFIC PROGRAMME (continued)

O31	10.15–11.45	Public Health Perspectives in Viral Hepatitis: Building-up a Public Health Response to Viral Hepatitis B and C Epidemics in the Region of the Americas <i>In collaboration with the Pan American Health Organization (PAHO)</i>
O31CH		Chair: <i>Massimo N Ghidinelli, Pan American Health Organization/World Health Organization, Washington DC, USA</i>
O311	10.15–10.30	Viral hepatitis B and C in the Americas <i>Massimo N Ghidinelli</i>
O312	10.30–10.45	What would it take to eliminate hepatitis B and C in the region of the Americas? <i>Homie Razavi, Center for Disease Analysis, Louisville, USA</i>
O313	10.45–11.00	Access to compassionate treatment for HCV in Argentina: review of 1 year's experience <i>Gabriela Vidiella, Ministerio de Salud de la Nación, and Fundación del Centro de Estudios Infecciosos (FUNCEI), Buenos Aires, Argentina</i>
O314	11.00–11.15	Expanding access to HCV treatment: treatment priorities and overcoming barriers <i>Adele Schwartz Benzaken</i>
O315	11.15–11.30	Elimination of HBV perinatal transmission: how far from achievement? <i>Chloe Thio, The Johns Hopkins University, Baltimore, USA</i>
	11.30–11.45	Discussion
O32	11.45–13.15	Implementation Science and New Relevant Data
O32CH		Co-Chairs: <i>Daniel R Kuritzkes, Brigham and Women's Hospital, Harvard Medical School, Boston, USA</i>
O32CH		<i>Ian Weller, University College London Medical School, London, UK</i>
O321	11.45–12.00	Review of key data since the 2016 Americas Congress <i>Ricardo Sobhie Diaz</i>
O322	12.00–12.15	Update from CROI <i>Luis Soto-Ramirez, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico</i>
O323*	12.15–12.30	Efficacy and safety of switching to EVG/COBI/FTC/TAF in virologically suppressed women <i>Monica Thormann</i>
O324*	12.30–12.45	Significant efficacy and long-term safety difference with TAF-based STR in treatment-naïve adults <i>Carlos Falistocco, Gilead SUD America, Vicente Lopez, Argentina</i>
O325	12.45–13.15	Implementation challenges: a regional perspective <i>Juan Sierra-Madero</i>
	13.15–14.15	Scientific Posters and lunch

*Abstract accepted for oral presentation.

SCIENTIFIC PROGRAMME (continued)

CS2	14.15–15.30	Challenging Cases in HIV Interactive Case Study Session in Collaboration with the International Antiviral Society–USA (IAS–USA)
CS2CH		Chair: <i>Roy M Gulick</i>
CS21	14.15–14.40	Issues in opportunistic infection prevention: focus on tuberculosis <i>Patrice Sévère, Haitian Study Group on Kaposi's Sarcoma and Opportunistic Infections, GHESKIO, Port-au-Prince, Haiti</i>
CS22	14.40–15.05	Prepping for pre-exposure prophylaxis (PrEP) <i>Alicia Piñeirúa Menéndez, Clínica Especializada Condesa Iztapalapa, Ciudad de México, Mexico</i>
CS23	15.05–15.30	Antiretroviral therapy: what to start <i>Omar Sued, Fundación Huésped, Buenos Aires, Argentina</i>
O33	15.30–16.30	Closing Lectures
O33CH		Co-Chairs: <i>Mauro Schechter</i>
O33CH		<i>Juan Sierra-Madero</i>
O331	15.30–16.00	Treatment as prevention in HCV and drug users covering hepatitis B and C <i>Esteban Gonzalez Ballerga</i>
O332	16.00–16.30	New ART strategies and the future of ART <i>Daniel R Kuritzkes</i>
	16.30–16.45	Conference Close

SCIENTIFIC PROGRAMME (continued)

Submitted abstracts accepted for oral presentation within the Scientific Programme, illustrating full author group and affiliations.

- O132 **Retreatment of patients failing AAD therapy in Spain in a real-life setting: updated results from the HEPCREsp GEHEP004 Cohort**
*Ana Belen Perez¹; Natalia Chueca¹; Jose Angel Fernandez Caballero¹; Miguel Garcia-del Toro²; Juan Manuel Pascasio³; Francisco Tellez⁴; Juan Antonio Pineda⁵; Francisco Vera⁶; Antonio Collado⁷; Juan Carlos Alados⁸; Federico Garcia^{*1}, on behalf of the GEHEP-004 Group*
¹Department of Clinical Microbiology, Hospital Universitario San Cecilio, Granada, Spain; ²Department of Infectious Diseases, Hospital General, Valencia, Spain; ³Department of Hepatology, Hospital Virgen del Rocío, Sevilla, Spain; ⁴Department of Infectious Diseases, Hospital Puerto Real, Cadiz, Spain; ⁵Department of Infectious Diseases, Hospital de Valme, Sevilla, Spain; ⁶Department of Infectious Diseases, Hospital Cartagena, Cartagena, Spain; ⁷Department of Infectious Diseases, Hospital Torrecardenas, Almería, Spain; ⁸Department of Clinical Microbiology, Hospital de Jerez, Cadiz, Spain
- O133 **Increased age-adjusted mortality and incidence of non-AIDS-defining events among people living with HIV enrolled after 50 years and aging in care in Latin America. A CCASANet Cohort study**
*Pablo F Belaunzarán-Zamudio^{*1}; Yanink Neried Caro-Vega¹; Brenda Crabtree-Ramirez¹; Bryan Shepherd²; Fernando Mejía³; Mark Giganti⁴; Beatriz Grinsztejn⁵; Marcelo Wolff⁶; Jean W Pape⁷; Denis Padgett⁸; Catherine Mc Gowan⁹; Juan Sierra-Madero¹*
¹Department of Infectology, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico; ²Department of Biostatistics, Vanderbilt University, Nashville, USA; ³Infectious Disease Clinic, Universidad Peruana Cayetano Heredia, Lima, Peru; ⁴Biostatistics Department, Vanderbilt University, Nashville, USA; ⁵Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil; ⁶Department of Infectious Diseases, Fundacion Arriaran, Santiago de Chile, Chile; ⁷Integrated Care Center and Research Institute, Les Centres GHESKIO, Port-au-Prince, Haiti; ⁸Department of Infectious Diseases, Hospital Escuela Universitario, Tegucigalpa, Honduras; ⁹Department of Medicine, Vanderbilt University, Nashville, USA
- O323 **Efficacy and safety of switching to EVG/COBI/FTC/TAF in virologically suppressed women**
*Monica Thormann^{*1}; Sally Hodder²; Kathleen Squires³; Cissy Kityo⁴; Debbie Hagins⁵; Anchalee Avihingsanon⁶; Yulia Plotnikova⁷; Shuping Jiang⁸; Rima Kulkarni⁹; Andrew Cheng⁸; Huyen Cao⁹*
¹Infectious Diseases Department, Salvador B Gautier Hospital, Santo Domingo, Dominican Republic; ²Infectious Diseases Department, West Virginia Clinical and Translational Science Institute, Morgantown, USA; ³Infectious Diseases Department, Thomas Jefferson University, Philadelphia, USA; ⁴Infectious Diseases Department, Joint Clinical Research Center, Kampala, Uganda; ⁵Infectious Diseases Department, Ryan White CARE Clinics, Savannah, USA; ⁶Infectious Diseases Department, HIVNAT, Thai Red Cross AIDS Research Center, Bangkok, Thailand; ⁷Infectious Diseases Department, Irkutsk Regional Center for Prevention and Control of AIDS and Infectious Diseases, Irkutsk, Russian Federation; ⁸GSI, Clinical Research, Foster City, USA; ⁹GSI, Clinical Research, Foster City, USA
- O324 **Significant efficacy and long-term safety difference with TAF-based STR in treatment-naïve adults**
*Carlos Falisticco^{*1}; Jose Arribas²; Melanie Thompson³; Paul Sax⁴; Bernhard Haas⁵; Cheryl McDonald⁶; David Wohl⁷; Edwin DeJesus⁸; Amanda Clarke⁹; Scott McCallister¹⁰; Moupali Das¹⁰*
¹Public Health and Medical Affairs, Gilead SUD America, Vicente Lopez, Argentina; ²Hospital Universitario, La Paz, Madrid, Spain; ³AIDS Research Consortium, Atlanta, USA; ⁴Brigham and Womens Hospital, Boston, USA; ⁵General Hospital Graz West, Graz, Austria; ⁶Tarrant County Infectious Disease Associates, Fort Worth, USA; ⁷UNC School of Medicine, Chapel Hill, USA; ⁸Orlando Immunology Center, Orlando, USA; ⁹Brighton & Sussex University Hospital, NHS Trust, Brighton, UK; ¹⁰Gilead Science, Foster City, USA

*Indicates presenting author.